Key result
Combination antithrombotics post-PCI yield clinical improvement without major bleeding in a severe COVID-19 NSTE-ACS case.
Why the study?
Experience with combination antithrombotic therapy in acute coronary syndrome patients with severe COVID-19 infection is limited and requires clinical evaluation.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Aggressive combination antithrombotic therapy may be safe and effective in patients with NSTE-ACS and severe COVID-19.
The paper presents the experience of treating a patient with acute coronary syndrome without ST segment elevation and underlying severe novel coronavirus infection (COVID-19) complicated by polysegmental viral pneumonia and significant respiratory events. Emphasis has been placed on the use of antithrombotic therapy after endovascular treatment. A 56-year-old patient underwent respiratory support (non-invasive face mask lung ventilation followed by high-flow oxygenation), urgent diagnostic coronary angiography followed by percutaneous coronary intervention (balloon angioplasty and stenting of the right coronary artery and anterior interventricular artery). In addition to the etiopathogenetic therapy for coronavirus infection, the patient received combination antithrombotic therapy, including acetylsalicylic acid, prasugrel, FRaMon monoclonal antibodies (single exposure, intraoperatively), sodium enoxaparin. The therapy resulted in normalization of hemodynamic parameters, stable normothermia, absence of catarrhal events, improvement of exercise tolerance. A chest ultrasound imaging showed consolidation events, inflammatory markers significantly decreased, circulatory deficiency events were compensated, anginal pains did not recur. On the 20th day of hospitalization, the patient was discharged home with outpatient follow-up. The use of potent antiplatelet agents such as prasugrel or ticagrelor combined with IIb/IIIa receptor inhibitors and prolonged anticoagulant therapy can potentially improve the outcome of the disease in acute coronary syndrome with underlying severe coronavirus infection. In the presented clinical example, the use of aggressive approaches to the antithrombotic therapy did not lead to the development of significant hemorrhagic or other complications.
No takes yet. Share an insight, caveat, or question.
Kurenkov et al. (2022) conducted a case report in Acute coronary syndrome without ST segment elevation and severe COVID-19 (n=1). Combination antithrombotic therapy (acetylsalicylic acid, prasugrel, FRaMon monoclonal antibodies, sodium enoxaparin) was evaluated on Clinical recovery and absence of hemorrhagic complications. Combination antithrombotic therapy including prasugrel, IIb/IIIa receptor inhibitors, and enoxaparin after PCI in a patient with NSTE-ACS and severe COVID-19 resulted in clinical improvement without significant hemorrhagic complications.
Synapse has enriched 10 related papers. Consider them for comparative context: